A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients With Diabetic Gastroparesis
A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients With Diabetic Gastroparesis
This study will evaluate the safety and efficacy of relamorelin compared to placebo in participants with diabetic gastroparesis. Participants will report daily severity scores of their diabetic gastroparesis symptoms.
Inclusion Criteria:
Exclusion Criteria:
Metairie, Louisiana 70006, United States
Frederick, Maryland 21701, United States
Adelaide, South Australia 5000, Australia
Hyderabad, Andhra Pradesh 500072, India
Ahmedabad, Gujarat 380007, India
Odesa, Odesa Oblast 65025, Ukraine
Vinnitsa, Vinnytsia Oblast 21050, Ukraine
Chernivtsi, 58001, Ukraine
Dnipro, 49027, Ukraine
Kharkiv, 61039, Ukraine
Kharkiv, 61070, Ukraine
Kyiv, 2002, Ukraine
Kyiv, 4050, Ukraine
Odesa, 65010, Ukraine
Vinnytsia, 21029, Ukraine